Target $97.

Cantor Fitzgerald raised the firm's price target on Eli Lilly to $885 from $815 and keeps an Overweight rating on the shares. Despite the top-line miss that was widely anticipated due to incretin supply constraints, Eli Lilly's sales growth of 26% in Q1 is still impressive, the analyst tells investors in a research note. Zepbound is already annualizing at over $2B annually in the first full quarter into its launch, positioning the drug for tens of billions of sales, which means there could be upside to already bullish forecasts for Zepbound, and Lilly is well positioned to deliver on future growth with other key pipeline drugs and indications, Cantor says.

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.  1... To see the rest of the story go to thefly.com. See Story Here

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.  1... To see the rest of the story go to thefly.com. See Story Here

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here

Consensus $12.50. Raises FY24 revenue view to $42.4B-$43.6B from $40.4B-$41.6B, consensus $41.44B. Raises FY24 gross margin view to 33%-35% from 31%-33%. Sees FY24 tax rate 14%.